Pci Biotech As
Clinical Trials
25
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (22 trials with phase data)• Click on a phase to view related trials
PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer
- Conditions
- Cholangiocarcinoma
- Interventions
- Drug: Gemcitabine/Cisplatin chemotherapy
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- PCI Biotech AS
- Target Recruit Count
- 41
- Registration Number
- NCT04099888
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Emory University Hospital, 1365C Clifton Road NE, Atlanta, Georgia, United States
🇺🇸University of Chicago Medical Center, 5841 South Maryland Avenue, Chicago, Illinois, United States
Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant
- Conditions
- Healthy Volunteer
- Interventions
- Biological: Hiltonol (Poly-ICLC)Biological: HPV E7 (Human Papilloma Virus E7) peptidesBiological: KLH (Keyhole Limpet Hemocyanin)
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- PCI Biotech AS
- Target Recruit Count
- 96
- Registration Number
- NCT02947854
- Locations
- 🇬🇧
Covance Clinical Research Unit Limited, Leeds, United Kingdom
A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas
- Conditions
- Cholangiocarcinoma
- Interventions
- Drug: Amphinex, Gemcitabine and Cisplatin
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- PCI Biotech AS
- Target Recruit Count
- 24
- Registration Number
- NCT01900158
- Locations
- 🇫🇷
CHU Angers, Angers, Maine-et-Loire, France
🇩🇪Klinikum rechts der Isar, Technische Universität München, Munich, Bayern, Germany
🇩🇪Klinikum der Ludwig-Maximilians-Universität, München, Bayern, Germany
Dose Escalating Study for Amphinex-based PCI of Bleomycin.
- Conditions
- Cutaneous or Sub-cutaneous Malignancies
- Interventions
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2014-06-16
- Lead Sponsor
- PCI Biotech AS
- Target Recruit Count
- 3
- Registration Number
- NCT01872923
- Locations
- 🇬🇧
University College London Hospital, London, United Kingdom
A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer.
- Conditions
- Recurrent Head and Neck CancerCarcinoma, Squamous Cell of Head and Neck
- Interventions
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- PCI Biotech AS
- Target Recruit Count
- 26
- Registration Number
- NCT01606566
- Locations
- 🇫🇷
CHU de Nantes Hôtel Dieu, Nantes, Nantes Cedex 1, France
🇫🇷Centre Alexis Vautrin (CAV)-Nancy Université, Nancy, France
🇩🇪Universitätsklinikum Schleswig-Holstein, Lübeck, Schleswig-Holstein, Germany
- Prev
- 1
- 2
- Next